Cancer is major research focus at Imperial College London. We have built an innovative cancer research and basic science portfolio, complemented with cutting edge technologies.
Coupled with strong collaborations and evidence based medical approaches through clinical trials, we strive to translate our research into cancer treatments in the quickest possible time.
One of the keys to an improved understanding of cancer, from diagnosis to treatment, is to appreciate the mechanisms that cancer cells use to divide and metastasise. As many individuals relapse following initial therapy, it is crucial to identify the factors implicated in resistance to standard therapy, with the ultimate aim of increasing the cure rate.
One of our major objectives is to enhance cancer prevention and improve treatment outcome for patients. This is achieved through an understanding of how key biochemical pathways are changed in cancer, the underlying genetic and epigenetic alterations driving these biochemical changes and using this knowledge to stratify patients for the best molecularly targeted therapies.
Our current research centres are a testament to the excellence in cancer research at Imperial:
In conjunction with ICR, we have also established the Centre for Systems Oncology and Cancer Innovation which builds on the complementary expertise of both institutions.